Quantcast
Last updated on April 23, 2014 at 13:57 EDT

Latest balance disorders Stories

Magnetic Pull Of MRI Could Diagnose, Treat And Study Inner Ear Disorders
2014-03-20 08:52:28

Johns Hopkins Medicine Magnetic pull of MRI shown in zebrafish and in people with common inner-ear disturbance Expanding on earlier research, Johns Hopkins researchers report that people with balance disorders or dizziness traceable to an inner-ear disturbance show distinctive abnormal eye movements when the affected ear is exposed to the strong pull of an MRI's magnetic field. The researchers first reported in 2011 in the journal Current Biology that an MRI's magnetic field pushes...

2014-02-13 08:30:01

GAITHERSBURG, Md., Feb. 13, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed...

2013-11-12 08:34:57

GAITHERSBURG, Md., Nov. 12, 2013 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced financial results for the third quarter and nine months ended September 30, 2013. Third Quarter and Recent Corporate Highlights -- Following an extensive review of the company's options and prospects, the board of directors withdrew the Plan of Complete Liquidation and Dissolution and approved a new operating strategy focused on maximizing the value of GenVec's...

2011-12-06 06:58:00

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities. "Completing this milestone reflects sustained progress and we look forward to reaching additional milestones with Novartis in...

2011-11-28 20:32:08

State-of-the-art in vestibular rehabilitation presented in a special issue of NeuroRehabilitation Over the last 25 years, intensive efforts by physicians, physical therapists, and occupational therapists have developed integrative rehabilitation regimens that can alleviate balance disorders associated with neurological disease, trauma or weightlessness. A special issue of NeuroRehabilitation: An Interdisciplinary Journal provides an up-to-date review of the underlying scientific principles...

2011-08-09 06:00:00

GAITHERSBURG, Md., Aug. 9, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced its financial results for the three months and six months ended June 30, 2011. "During the second quarter we made significant progress in key programs including our collaboration with Novartis to develop treatments for hearing loss and balance disorders," said Dr. Paul Fischer, President and Chief Executive Officer. "We enter the second half of 2011 with strong momentum and look ahead to achieving...

2011-03-10 15:15:00

GAITHERSBURG, Md., March 10, 2011 /PRNewswire/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced financial results for the fourth quarter and year ended December 31, 2010. For the year ended December 31, 2010, the Company reported a net loss of $12.3 million, or $0.10 per share, compared with a net loss of $18.4 million, or $0.19 per share, for the year ended December 31, 2009. GenVec ended the year with $35.2 million in cash, cash equivalents, and short-term investments. "In 2010 we...

2010-09-14 06:28:00

GAITHERSBURG, Md., Sept. 14 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the first milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities. "Completion of this milestone signifies progress made in moving the potential product toward clinical development," said Dr. Paul...

2010-08-06 06:24:00

GAITHERSBURG, Md., Aug. 6 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) today announced a new agreement for the supply of services relating to development materials with Novartis, related to the companies' collaboration in hearing loss and balance disorders. Under this new agreement, GenVec could receive approximately $13 million over four years to manufacture clinical trial material for up to two lead candidates. "This contract supports our ongoing collaborative efforts with...

2007-10-09 12:00:40

NASHVILLE, Tenn., Oct. 9 /PRNewswire/ -- Premier Micronutrient Corporation (PMC) announces the launch of a Hearing Health micronutrient supplement designed to reduce tinnitus (ringing in the ear) and provide cellular protection against hearing impairment and balance disorders. Previously available only to scientific study participants and members of the U.S. military, the Hearing Health formulation is now available to a general consumer audience through hearing health professionals and the...